Loading...
This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.
Click here to view the deleted recordCe document a été mis à jour. Il ne s’agit pas de la dernière version publiée. Cliquez ici pour voir la dernière version du fichier.
Organisme vivant modifié
(LMO)
L’image ci-dessous identifie l’OVM par son identificateur unique, son nom commercial et un lien vers cette page du Centre d’échange Cliquer dessus pour télécharger une plus grande image sur votre ordinateur Pour du soutien sur comment utiliser, aller dans la page de liens rapides OVM.
VECTORMUNE® FP-MG + AE
EN
Vectormune FP-MG + AE
Non
VECTORMUNE® FP-MG+AE
-
Organisation :Ceva Saúde Animal Ltda (CEVA)Secteur privé (affaires et industrie)Rua Manuel Joaquim Filho, 303 Pulínia - SPPaulínia, São Paulo
13140-000,Téléphone : 551938337700,Télécopieur : 55193833-7722,E-mail : alexisgoux@ceva.com,Site Web : http://www.ceva.com.br/,
VECTORMUNE® FP MG + AE is a genetically modified live virus vaccine for the vaccination of chickens as an aid in the prevention of fowl pox and Mycoplasma gallisepticum. The fowl pox vaccine has been genetically engineered to contain and express key protective Mycoplasma gallisepticum bacterial antigens, the MG 40k and the mgc3 genes. In addition to the fowlpox virus vector, this freeze-dried vaccine contains a conventional live avian encephalomyelitis (AE) virus for use as an aid in the prevention of avian encephalomyelitis.
Le terme « organisme récepteur » désigne un organisme (non modifié ou déjà modifié) ayant fait l'objet d'une modification génétique, tandis que les « organismes parentaux » désignent les organismes impliqués dans un croisement ou une fusion cellulaire pour générer un organisme modifié.
-
BCH-ORGA-SCBD-105337-2 Organisme Mycoplasma gallisepticum (MG, MYCGL)Bactéries
-
BCH-LMO-SCBD-105419-1 Organisme vivant modifié VECTORMUNE® FP MG VaccineCeva Saúde Animal Ltda(CEVA) | Production de composés médicaux ou pharmaceutiques (humains ou animaux) (Vaccins)
-
BCH-ORGA-SCBD-105171-4 Organisme Fowlpox virus (FOWPV)Virus
Fowlpox virus strain Cutter
EN
-
VECTORMUNE® FP MG Vaccine| Ceva Saúde Animal Ltda(CEVA) | Production de composés médicaux ou pharmaceutiques (humains ou animaux) (Vaccins)
pUC18
EN
- Transgénèse par infection virale
Certains de ces éléments génétiques peuvent être présents sous forme de fragments ou sous forme tronquée. Veuillez consulter les notes ci-dessous, s’il y a lieu.
-
BCH-GENE-SCBD-105411-1 MG 40k antigen gene | Mycoplasma gallisepticum (MG, MYCGL)Séquence codante de protéines | Production de composés médicaux ou pharmaceutiques (humains ou animaux) (Vaccins)
-
BCH-GENE-SCBD-105360-1 mgc3 gene | Mycoplasma gallisepticum (MG, MYCGL)Séquence codante de protéines | Production de composés médicaux ou pharmaceutiques (humains ou animaux) (Vaccins)
Information on the DNA sequences
The DNA insert to the vector comprised two genetic cassettes expressing the MG 40K and mcg3 genes derived from Mycoplasma gallisepticum.
(1) The expression of the MG 40K gene is directed by the synthetic Ps promoter, which emulates the consensus early/late promoter of poxvirus, and a termination sequence derived from the gB gene of the Marek Disease Virus (MDV) was also inserted into the pUC18 vector. A MDV gB transit signal sequence was added to the 3' terminus of the of MG 40K and mcg3 coding sequences to ensure localization to the cell membrane.
(2) The expression of the mcg3 gene was similarly under the control of the synthetic Ps promoter, the MDV gB transit signal sequence, and the gB terminator.
Note
The DNA insert to the vector comprised two genetic cassettes expressing the MG 40K and mcg3 genes derived from Mycoplasma gallisepticum.
(1) The expression of the MG 40K gene is directed by the synthetic Ps promoter, which emulates the consensus early/late promoter of poxvirus, and a termination sequence derived from the gB gene of the Marek Disease Virus (MDV) was also inserted into the pUC18 vector. A MDV gB transit signal sequence was added to the 3' terminus of the of MG 40K and mcg3 coding sequences to ensure localization to the cell membrane.
(2) The expression of the mcg3 gene was similarly under the control of the synthetic Ps promoter, the MDV gB transit signal sequence, and the gB terminator.
Note
- A 3kb Hpal-Spel fragment of the Fowl Pox Virus (FPV) genome was inserted into a EcoR1-HindIII site of a pUC18 vector. The homologous recombination site may be interrupting a possible open reading frame but is thought to be non-essential for viral replication and has no known function in the FPV.
- A 175bp EcoRV fragment of the FPV genome was removed from this construct and replaced with the MG 40K and mcg3 coding sequences.
- Mycoplasma gallisepticum strains S6 and R are mentioned as donors, but the specific strain of the vaccine's the MG 40K and the mgc3 sequences are derived from are not identified.
- This construct and the attenuated parental FPV strain were co-transformed into chicken embryo fibroblasts (CEF) and incubated under conditions that favor homologous recombination.
- After transfection, viral particles were cultivated from the chicken embryo fibroblasts and assayed for expression of MG 40K and mcg3 proteins. Plaques expressing MG 40K and mcg3 proteins were isolated and selected until the pure recombined virus was obtained.
FR
- Vaccin
FR
The vaccine contains a genetically modified live virus (prevention of Boubabaum for FowlpoxV virus) and Mycoplasma galliseptic genes by inserting this bacterium into the virus. The BA virus was modified by genetic engineering and expressed key protective MG antigens. The vaccine is presented in lyophilized form and is recommended for active immunization of healthy chickens to protect against Fowl Pox and MG, for administration via puncture in the wing membrane. A conventional attenuated sample of avian encephalomyelitis (AE) will be added to this vaccine.
- CTNBio Technical Opinion 2226/2009: Developer's Request on biosafety of a genetically modified organism for activities of Vectormune FP MG AE [PDF] ( Ministério da Ciência, Tecnologia, Inovações e Comunicações (MCTI); Solicitação de Aprovação de Liberação Comercial; Comissão técnica nacional de biossegurança; National Technical Commission on Biosafety; Parecer Técnico Nº 2226/2009 ) [ English ]
- USDA-APHIS (2019): Summary of Studies Supporting USDA Product Licensure – Avian Encephalomyelitis-Fowl Pox-Mycoplasma Gallisepticum Vaccine, Live Virus, Live Fowl Pox Vector [PDF] ( Product Compilation Summary 368-1D61R0 ) [ English ]
- CEVA leaflet: Vectormune FP MG AE [PDF] [ English ]
